Breaking News, Collaborations & Alliances

Isis, Alnylam Extend RNA Development Pact

Includes cross-license for two programs targeting thrombosis and cardiovascular disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals and Alnylam Pharmaceuticals have formed a new agreement, extending their existing strategic partnership from 2004 for the development and commercialization of RNA therapeutics. This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement also includes a non-exclusive technology cross-license, providing each company rights to certain techn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters